Loading...
Biodesix Inc (BDSX) shows strong revenue growth and improving gross margins, but its overbought technical indicators and insider selling suggest caution. For a beginner investor with a long-term focus, this stock is not an optimal buy right now. Consider holding off until technical indicators cool down or insider sentiment improves.
The stock is currently in an overbought condition with RSI_6 at 81.131. MACD is positive and expanding, indicating bullish momentum. Moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock closed near resistance levels (R1: 13.911, R2: 14.947), suggesting limited immediate upside.

Q4 2025 revenue increased by 40.76% YoY, indicating strong top-line growth.
Improved gross margins (up 5.43% YoY) and an expanded sales force.
Hedge funds are significantly increasing their positions, with a 1991.20% increase in buying activity over the last quarter.
Insiders are selling, with a 531.80% increase in selling activity over the last month.
The stock is overbought based on RSI_
The company reported a Q4 net loss of $3.98 million, and EPS dropped 56.25% YoY.
In Q4 2025, revenue grew by 40.76% YoY to $28.76 million, and gross margins improved to 83.03%. However, the company reported a net loss of $3.98 million, a 51.76% decline YoY, and EPS dropped to -0.49.
No data available for analyst ratings or price target trends.